GeneReach Biotechnology (4171) - Total Liabilities

Latest as of June 2026: NT$276.64 Million TWD ≈ $8.72 Million USD

Based on the latest financial reports, GeneReach Biotechnology (4171) has total liabilities worth NT$276.64 Million TWD (≈ $8.72 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4171 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

GeneReach Biotechnology - Total Liabilities Trend (2017–2025)

This chart illustrates how GeneReach Biotechnology's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of GeneReach Biotechnology.

GeneReach Biotechnology Competitors by Total Liabilities

The table below lists competitors of GeneReach Biotechnology ranked by their total liabilities.

Company	Country	Total Liabilities
Hub Cyber Security Ltd. Ordinary Shares NASDAQ:HUBC	USA	$136.85 Million
China Crystal New Material KQ:900250	Korea	₩21.94 Billion
Horizon Space Acquisition I Corp. Ordinary Shares NASDAQ:HSPO	USA	$6.10 Million
Abko Co. Ltd KQ:129890	Korea	₩46.18 Billion
Auking Mining Ltd AU:AKN	Australia	AU$1.81 Million
Skyline Builders Group Holding Limited Class A Ordinary Shares NASDAQ:SKBL	USA	$2.56 Million
DK&D Co.Ltd KQ:263020	Korea	₩33.55 Billion
Quickstep Holdings Ltd AU:QHL	Australia	AU$60.16 Million

Liability Composition Analysis (2017–2025)

This chart breaks down GeneReach Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GeneReach Biotechnology balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.48	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how GeneReach Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for GeneReach Biotechnology (2017–2025)

The table below shows the annual total liabilities of GeneReach Biotechnology from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$284.34 Million ≈ $8.96 Million	-16.62%
2024-12-31	NT$341.00 Million ≈ $10.74 Million	+8.70%
2023-12-31	NT$313.71 Million ≈ $9.88 Million	-39.58%
2022-12-31	NT$519.23 Million ≈ $16.36 Million	-12.93%
2021-12-31	NT$596.35 Million ≈ $18.79 Million	+55.81%
2020-12-31	NT$382.75 Million ≈ $12.06 Million	+128.07%
2019-12-31	NT$167.82 Million ≈ $5.29 Million	-56.15%
2018-12-31	NT$382.68 Million ≈ $12.06 Million	+8.65%
2017-12-31	NT$352.21 Million ≈ $11.10 Million	--

About GeneReach Biotechnology

TWO:4171 Taiwan Biotechnology

Market Cap

$29.20 Million

NT$926.78 Million TWD

Market Cap Rank

#23955 Global

#1495 in Taiwan

Share Price

NT$16.30

Change (1 day)

+0.93%

52-Week Range

NT$16.15 - NT$26.50

All Time High

NT$246.40